Harrow (HROW) Non-Current Debt (2011 - 2026)
Harrow's (HROW) quarterly Non-Current Debt came in at $292.1 million in Q1 2026, up 159.63% year-on-year from $112.5 million in Q1 2025, and up 20.11% quarter-over-quarter from $243.2 million in Q4 2025.
Harrow (HROW) Non-Current Debt (2011 - 2026) Analysis & Trends
Harrow's Non-Current Debt history runs 13 years deep, the most recent figure standing at $292.1 million for Q1 2026.
- On a quarterly basis, Non-Current Debt rose 159.63% year-over-year to $292.1 million in Q1 2026; TTM through Mar 2026 was $292.1 million, a 159.63% increase from a year earlier, with the FY2025 full-year figure at $243.2 million, up 10.77% from the prior year.
- Non-Current Debt rose to $292.1 million in Q1 2026 per HROW's latest filing, from $243.2 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $292.1 million in Q1 2026 and bottomed at $38.5 million in Q2 2025.
- The 5-year median for Non-Current Debt is $182.2 million (2023), against an average of $160.6 million.
- Across the five-year window, Non-Current Debt surged 553.39% in 2022 and slumped 79.2% in 2025, its largest moves.
- Year by year, Non-Current Debt stood at $104.2 million in 2022, then jumped by 78.44% to $185.9 million in 2023, then increased by 18.1% to $219.5 million in 2024, then gained by 10.77% to $243.2 million in 2025, then rose by 20.11% to $292.1 million in 2026.
- Per Business Quant, the three latest HROW Non-Current Debt figures stand at $292.1 million (Q1 2026), $243.2 million (Q4 2025), and $242.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 292.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 292.09 Mn |
| Dec 31, 2025 | 243.18 Mn |
| Sep 30, 2025 | 242.87 Mn |
| Jun 30, 2025 | 38.48 Mn |
| Mar 31, 2025 | 112.50 Mn |
| Dec 31, 2024 | 219.54 Mn |
| Sep 30, 2024 | 186.06 Mn |
| Jun 30, 2024 | 185.02 Mn |
| Mar 31, 2024 | 184.15 Mn |
| Dec 31, 2023 | 185.89 Mn |
| Sep 30, 2023 | 182.19 Mn |
| Jun 30, 2023 | 169.71 Mn |
| Mar 31, 2023 | 168.85 Mn |
| Dec 31, 2022 | 104.17 Mn |
| Sep 30, 2022 | 72.24 Mn |
| Jun 30, 2022 | 72.04 Mn |
| Mar 31, 2022 | 71.85 Mn |
| Dec 31, 2021 | 71.65 Mn |
| Sep 30, 2021 | 71.46 Mn |
| Jun 30, 2021 | 71.27 Mn |